In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody

With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c‐erbB‐2 gene product, and the other arm recognized CD3ɛ, a T‐cell specific surface antigen. Application of this BFA wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugiyama, Yoshihiro, Aihara, Miki, Shibamori, Masafumi, Deguchi, Kyohei, Imagawa, Kenichi, Kikuchi, Mikio, Momota, Hiroshi, Azuma, Takachika, Okada, Hidechika, Alper, Özge, Hitomi, Jiro, Yamaguchi, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1992
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918874/
https://www.ncbi.nlm.nih.gov/pubmed/1353752
http://dx.doi.org/10.1111/j.1349-7006.1992.tb00126.x
Descripción
Sumario:With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c‐erbB‐2 gene product, and the other arm recognized CD3ɛ, a T‐cell specific surface antigen. Application of this BFA with human peripheral blood lymphocytes exhibited specific anti‐tumor activity in vitro on a breast tumor cell line, ZR‐75–1, which expressed abundant c‐erbB‐2 gene product on its cell surface. These results indicate that BFA recognizing an oncogene product on cell surface is a potential new agent for cancer immunotherapy.

Ejemplares similares